Which patients benefit most from tirzepatide GLP-1 for obesity and obstructive sleep apnea?Which patients benefit most from tirzepatide GLP-1 for obesity and obstructive sleep apnea?
Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally. Now, new research presented at the 2026 ATS International Conference narrows down which patients are likely to have the best treatment outcomes. Tirzepatide GLP-1 medication is known to improve sleep Read More
GLP-1 Drugs Linked to Significant Boost in Testosterone Levels for MenGLP-1 Drugs Linked to Significant Boost in Testosterone Levels for Men
(MedPage Today) — WASHINGTON — Men treated with GLP-1 receptor agonists had significant increases in testosterone levels, according to findings from a retrospective analysis. Among men who received semaglutide (Ozempic, Wegovy) or tirzepatide… (MedPage Today) — WASHINGTON — Men treated with GLP-1 receptor agonists had significant increases in testosterone levels, according to findings from Read More
What is ‘Ozempic Personality’? How GLP-1s Can Affect MoodWhat is ‘Ozempic Personality’? How GLP-1s Can Affect Mood
GLP-1s like Wegovy and Zepbound are transforming the weight loss landscape but along with physical changes, a number of patients are reporting a loss in joy or pleasure. The reports of the unexpected side effect, which some dub “Ozempic personality,” are all anecdotal but weight loss drug patients across social media are opening up in Read More
Long-term trial challenges assumptions about lymph node radiation therapy in breast cancerLong-term trial challenges assumptions about lymph node radiation therapy in breast cancer
Final results from a landmark EORTC randomized trial with more than 20 years of follow-up show that irradiation of the internal mammary and medial supraclavicular lymph nodes reduces breast cancer mortality but does not improve overall survival. The findings highlight the importance of very long-term follow-up when evaluating cancer treatments, particularly in patients with an otherwise favorable prognosis.
STAT+: Maryland state affordability board places a price cap on OzempicSTAT+: Maryland state affordability board places a price cap on Ozempic
The Maryland Prescription Drug Affordability Board agreed to set an upper payment limit for the Ozempic diabetes treatment, marking the second time that the state panel has taken such a step in recent weeks. The board, which is designed to function like a state utility commission, will now oversee a process to lower the cost Read More
At ‘most favored nation’ prices, can Medicare break even on GLP-1 drugs?At ‘most favored nation’ prices, can Medicare break even on GLP-1 drugs?
In November 2025, the White House announced pricing deals with multiple pharmaceutical manufacturers to lower domestic prices for glucagon-like peptide-1 receptor agonist drugs (GLP-1RAs) including Ozempic, Wegovy, Mounjaro, and Zepbound. Those deals are part of a new “most favored nation” (MFN) policy that ties the cost of GLP-1RAs in the U.S. to the prices paid Read More
Blockbuster Drug Gets Breast Cancer Approvals in Curative SettingBlockbuster Drug Gets Breast Cancer Approvals in Curative Setting
(MedPage Today) — The FDA on Friday approved two new trastuzumab deruxtecan (T-DXd; Enhertu) indications for treating early-stage breast cancer patients with HER2-positive disease.
In the neoadjuvant setting, the first indication is for stage…
Open-access tool decodes DNA change patterns in breast cancerOpen-access tool decodes DNA change patterns in breast cancer
A study led by Dr. Jason Pitt, Principal Investigator at the Cancer Science Institute of Singapore (CSI Singapore), has identified eight new “signatures” of DNA patterns (gains and/or losses) in breast cancer. By analyzing nearly 2,800 genomes, the team systematically profiled changes in the number of DNA copies in breast cancer, with the goal of better understanding the underlying mechanisms of tumor development and evaluating how these structural genomic changes relate to clinical outcomes.
ESTRO: Select breast cancer patients may be able to omit surgery following ablative radiationESTRO: Select breast cancer patients may be able to omit surgery following ablative radiation
A select group of patients with early-stage breast cancer were able to omit surgery with no tumor progression after three years, according to results of a Phase 2 trial of ablative radiation therapy and endocrine therapy led by researchers at The University of Texas MD Anderson Cancer Center.
GLP-1 receptor agonists move from weight loss into the longevity conversationGLP-1 receptor agonists move from weight loss into the longevity conversation
GLP-1 receptor agonists move from weight loss into the longevity conversation GLP-1 receptor agonists are quickly shifting from niche metabolic drugs to something much broader in clinical conversation. What started as a treatment for type 2 diabetes is now firmly embedded in obesity care and increasingly discussed in the context of long term health and Read More